ESPR

Esperion

Last Updated:

Q1 '20

Price

quotes and stock data delayed 15 minutes

Cash

$215.7M

Burn Rate (Qtr)

$85.4M

Company Profile

ESPERION is passionately committed to developing and commercializing oral, LDL-C lowering therapies for patients with hypercholesterolemia.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Bempedoic Acid (Nexletol)

Elevated LDL-C (not adequately controlled with statins)

Quarterly Sales (approved)

February 26, 2021 (Est)

Bempedoic Acid/ Ezetimibe (Nexlizet)

Hypercholesterolemia

Quarterly Sales (Approved)

February 26, 2021 (Est)

Recent Posts

See what the community is saying - click to see full post

ESPR - NEXLETOL® (bempedoic acid) Tablets Demonstrating Significant Low-Density Lipoprotein Cholesterol (LDL-C

ESPR - ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update

ESPR - Esperion to Report Third Quarter 2020 Financial Results November 2, 2020

ESPR - Q2 2020 Net Sales

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon